Once the deal goes through, the French pharma giant will add an allogeneic natural killer (NK) cell therapy platform to its immune-oncology capabilities. In cell therapy development, industry has seen some success with T-cells, most notably in the approvals of the chimeric antigen receptor T-cell therapies Kymriah and Yescarta. T cells work by spurring patients’ adaptive immune system, which learns to remember threats and eliminates them when they return. However, NK cells, which are part of our innate immune system,…